June 20, 2025

3 things you missed in government this week

ADA News is providing a roundup of government happenings you may have missed this week.

ADA News

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

June 10, 2025

Castor Oil

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. ...

The ASCO Post

June 10, 2025

New Guidelines Challenge BMI Thresholds for Knee Surgery

ACR/AAHKS guideline conditionally recommends against delaying total knee arthroplasty based solely on BMI, prompting debate among orthopedic specialists.

Conexiant

June 04, 2025

New Guidelines Recommend Hypnotherapy, CBT for Pediatric Abdominal Pain

Joint ESPGHAN/NASPGHAN guidance outlines evidence-based treatments for functional abdominal pain and irritable bowel syndrome in pediatric patients.

Conexiant

May 30, 2025

Major Medical Societies Issue GLP-1 Nutrition Guidelines

New advisory addresses nutritional challenges and side effects for obesity treatment

Conexiant

September 28, 2023

Does Colon Tumor Location Play a Role in Metastasis and Survival?

A recent study examined survival outcomes among patients with right-sided vs left-sided colorectal tumors that had metastasized to the liver. The findings provide insight into the unique biology of ri...

The ASCO Post

December 04, 2023

Consuming Navy Beans May Improve Gut Health, Regulate Immune and Inflammatory Processes in Colorectal Cancer Survivors

Researchers investigated whether the regular consumption of navy beans could help improve the gut microbiome of colorectal cancer survivors.

The ASCO Post

November 13, 2023

FDA Approves Fruquintinib for Refractory Metastatic Colorectal Cancer

On November 8, the FDA approved an anti-VEGF tyrosine kinase inhibitor for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based che...

The ASCO Post